Results 131 to 140 of about 14,871 (183)
Some of the next articles are maybe not open access.
Chenodeoxycholic Acid: Uses and Limitations
Hospital Practice, 1979Conclusions about the efficacy and safety of this agent for dissolving cholesterol gallstones must wait until late next year, when results of large clinical trials are available. But results from many studies are available, as are preliminary clinical data from trials of a possible alternative, ursodeoxycholic acid.
openaire +2 more sources
Chenodeoxycholic Acid and Ursodeoxycholic Acid
1990Cholelithiasis (gallstones) is a major medical and economic problem in the USA (Schoenfield, 1977; Schoenfield et al., 1981). It has been estimated to have a prevalence of 15 million women and five million men, and almost one million new cases are discovered each year (Ingelfinger, 1968; Friedman et al., 1966).
Robert A. Maxwell, Shohreh B. Eckhardt
openaire +1 more source
The Formation of Deoxycholic Acid and Chenodeoxycholic Acid in Man
Clinical Science, 19741. The turnover of deoxycholic acid and chenodeoxycholic acid was studied in six normolipaemic patients after oral administration of trace amounts of isotopically labelled compounds. 2. The mean values for half-life, pool size and turnover of deoxycholic acid were 3·0 days, 663 mg and 171 mg/day respectively.
K, Einarsson, K, Hellström
openaire +2 more sources
Toxicity of Chenodeoxycholic Acid in the Rhesus Monkey
Gastroenterology, 1975Chenodeoxycholic acid is an important drug for the treatment of cholesterol cholelithiasis in man. Although no toxicity has been demostrated in man, liver lesions develop in rhesus monkeys treated with chenodeoxycholic acid. To elucidate the mechanism of toxicity, chenodeoxycholic acid.
H, Dyrszka +3 more
openaire +2 more sources
Gallstone dissolution with chenodeoxycholic acid
Klinische Wochenschrift, 1980Out of 95 patients with radiolucent gallstones who enrolled in a clinical study with chenodeoxycholic acid (CDC) for gallstone dissolution 75 patients with cholecystolithiasis completed 12 months of treatment. As a side effect 31% of patients reported intermittent diarrhea which did not cause cessation of therapy or missing of work.
H J, Weis +2 more
openaire +2 more sources
Polymorphism of chenodeoxycholic acid.
Il Farmaco; edizione scientifica, 1978Polymorphism of chenodeoxycholic acid was studied by differential thermal analysis and X-ray diffraction. Four polymorphic forms (three crystalline and one amorphous) were characterized.
G, Giuseppetti, M, Paciotti
openaire +1 more source
GALLSTONE DISSOLUTION BY CHENODEOXYCHOLIC ACID
The Lancet, 1973R H, Dowling, G D, Bell
openaire +4 more sources